SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PolyMedix
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (59)2/6/2014 12:43:05 PM
From: tuck  Read Replies (1) of 77
 
So, a year and a half later, another company (CTIX) is starting a P2b trial for Brilacidin. As Jason noted in the previous post, it is not a well funded company. Like PYMX, it also does not have a partner. With a trial expected to enroll over 200 patients and to be finished this year, and only a few million in cash on hand, the coming raise shouldn't surprise anyone. Nor should the ugliness of the terms. Can you say "lotsa warrants" or "20% discount to trailing 30 day average stock price?" I knew you could. The stock might be a buy after the 20% haircut; ceteris paribus, it should rise into the binary event. Might have to listen to a webcast to get a feel for management's strategy here. My guess would be that they'd seek a partner if the outcome is good. Meanwhile, the protocol:

Brilacidin P2B protocol

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News